Leiomyosarcoma Market

Market Overview:

The 7 major leiomyosarcoma markets are expected to exhibit a CAGR of 3.3% during 2024-2034.

The leiomyosarcoma market has been comprehensively analyzed in IMARC's new report titled "Leiomyosarcoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Leiomyosarcoma is a type of cancer that originates from smooth muscle cells. Smooth muscles are found in various body organs and tissues, such as the uterus, gastrointestinal tract, blood vessels, skin, etc. The symptoms of the ailment can vary depending on the size and location of the tumor, but common signs may include pain or discomfort in the affected area, the presence of a palpable mass or swelling, unexplained weight loss, fatigue, and, in some cases, symptoms related to compression or invasion of adjacent organs or structures. The diagnosis of leiomyosarcoma involves a combination of imaging studies and a biopsy. Several imaging techniques, including computed tomography (CT) scans and magnetic resonance imaging (MRI), help visualize the tumor and assess its characteristics and extent. A biopsy is then performed to obtain a tissue sample for histopathological examination, where a pathologist examines the sample under a microscope to confirm the presence of malignant smooth muscle cells. Several additional molecular pathology tests, such as immunohistochemistry and genetic analysis, may be conducted to further characterize the tumor and guide treatment decisions.

The increasing cases of certain genetic conditions, including hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome, which is characterized by the development of leiomyomas (benign smooth muscle tumors), are primarily driving the leiomyosarcoma market. Moreover, the escalating adoption of locoregional therapies to help control tumor growth and extend survival in patients with locally advanced or recurrent leiomyosarcoma is acting as another significant growth-inducing factor. Apart from this, the emerging popularity of various image-guided biopsies, such as CT-guided or ultrasound-guided biopsies, since they allow for precise sampling of the tumor while minimizing the risk of complications, is creating a positive outlook for the market. Furthermore, numerous key players are making extensive investments in the development of several therapies that can shrink tumors and facilitate surgical removal, thereby preserving organ function and improving the chances of achieving negative surgical margins. This, in turn, is also propelling the market growth. Additionally, the ongoing advancements in immunotherapeutic approaches, including the introduction of immune checkpoint inhibitors and adoptive cell therapies, which have demonstrated promising results in subsets of leiomyosarcoma patients, particularly those with high tumor mutational burden or microsatellite instability, are expected to drive the leiomyosarcoma market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the leiomyosarcoma market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for leiomyosarcoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the leiomyosarcoma market in any manner.

Key Highlights:

• Leiomyosarcoma makes up 10% to 20% of all newly diagnosed soft tissue sarcoma.
• Leiomyosarcoma is most usually found in the retroperitoneum, followed by the uterus, extremities, and trunk.
• Uterine sarcomas account for around 3% to 7% of all uterine cancers, with leiomyosarcoma being the most frequent subtype, accounting for over 80% of all uterine sarcomas.
• The incidence of leiomyosarcoma rises with age, peaking in the seventh decade of life.
• Women are more likely to develop retroperitoneal leiomyosarcoma and visceral blood vessel tumors, while men are more likely to develop numerous other types of cancer.

Drugs:

YONDELIS (trabectedin) is used to treat patients with unresectable or metastatic leiomyosarcoma who have previously received an anthracycline-based regimen. It is a new, multimodal, synthetic anticancer drug developed from the sea squirt Ecteinascidia turbinata. The anti-cancer drug works by preventing the tumor cells from proliferating.

Unesbulin is an experimental oral tubulin binding drug that stops tumor cells in G2/M phase, including cancer stem cells, by blocking tubulin polymerization. Unesbulin was found using PTC's proprietary discovery platform.

TTI-621 (SIRPa Fc) is being developed for the treatment of leiomyosarcoma. It is delivered by intratumoral and intravenous routes. SIRPaFc (TTI-621) is a fusion protein that combines the CD47-binding domain of human SIRPa with the Fc region of a human immunoglobulin (IgG1). The therapeutic candidate targets CD47.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the leiomyosarcoma market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the leiomyosarcoma market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current leiomyosarcoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the leiomyosarcoma market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the leiomyosarcoma market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the leiomyosarcoma market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of leiomyosarcoma across the seven major markets?
• What is the number of prevalent cases (2018-2034) of leiomyosarcoma by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of leiomyosarcoma by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with leiomyosarcoma across the seven major markets?
• What is the size of the leiomyosarcoma patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of leiomyosarcoma?
• What will be the growth rate of patients across the seven major markets?
   

Leiomyosarcoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for leiomyosarcoma drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the leiomyosarcoma market?
• What are the key regulatory events related to the leiomyosarcoma market?
• What is the structure of clinical trial landscape by status related to the leiomyosarcoma market?
• What is the structure of clinical trial landscape by phase related to the leiomyosarcoma market?
• What is the structure of clinical trial landscape by route of administration related to the leiomyosarcoma market?